WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use

Erin Sparrow, Ifedayo Adetifa, Nathorn Chaiyakunapruk, Thomas Cherian, Deshayne B Fell, Barney S Graham, Bruce Innis, David C Kaslow, Ruth A Karron, Harish Nair, Kathleen M Neuzil, Samir Saha, Peter G Smith, Padmini Srikantiah, Fred Were, Heather J Zar, Daniel Feikin

Research output: Contribution to journalArticlepeer-review

Abstract

World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies.

Original languageEnglish
Pages (from-to)3506-3510
JournalVaccine
Volume40
Issue number26
Early online date17 Feb 2022
DOIs
Publication statusPublished - 9 Jun 2022

Keywords

  • Antibodies, Monoclonal/therapeutic use
  • Antibodies, Viral
  • Child
  • Communicable Diseases
  • Humans
  • Immunization, Passive
  • Infant
  • Respiratory Syncytial Virus Infections/prevention & control
  • Respiratory Syncytial Virus Vaccines
  • Respiratory Syncytial Virus, Human
  • World Health Organization

Fingerprint

Dive into the research topics of 'WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use'. Together they form a unique fingerprint.

Cite this